Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
Poll|Articles|September 1, 2023
POLL: Do You Diagnose and Treat Psoriasis Through Telehealth Appointments?
Author(s)Dermatology Times Staff
Listen
0:00 / 0:00
Key Takeaways
- Telehealth usage in hospitals increased significantly from 2010 to 2017, with further growth expected post-pandemic.
- The COVID-19 pandemic accelerated telehealth integration, enhancing access to healthcare services.
Click here to answer this week’s poll.
Advertisement
Do you diagnose and treat psoriasis through telehealth appointments?
The use of telehealth in hospitals grew from 35% in 2010 to 76% in 20171, and since the COVID-19 pandemic, that number has likely increased. Do you diagnose and/or treat psoriasis through telehealth appointments?
Reference
- Fact Sheet: Telehealth. American Hospital Association. Accessed August 24, 2023.
https://www.aha.org/factsheet/telehealth#:~:text=Telehealth%20connects%20patients%20to%20vital,place%2C%20at%20the%20right%20time
Advertisement
Related to this article
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Advertisement
Advertisement
Trending on Dermatology Times
1
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
2
Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis
3
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
4
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
5